Rationale and design of the cardiovascular status in patients with endogenous cortisol excess study (CV-CORT-EX): a prospective non-interventional follow-up study

Patients with endogenous CS of any aetiology (i.e. pituitary adenoma, ectopic tumour, or adrenal adenoma / hyperplasia) will be considered eligible if the inclusion and exclusion criteria (given in Table 1) are fulfilled. In contrast, patients with iatrogenic CS or adrenal carcinoma will not be enrolled, as the course of the disease is expected to result in a different clinical picture and outcome.

At study start, endogenous CS may either be overt or in remission. Care will be taken that former diagnosis of CS was made according to published guidelines [22]. Cases with adrenal disease (i.e., an adenoma or hyperplasia), inadequate response (i.e., a serum cortisol of ≥1.8 μg/dl) during the 1 mg overnight dexamethasone suppression test (1-mg-DST), and no clinical features of CS will be classified as mild autonomous cortisol excess (MACE) [23].

Study-specific investigations will be performed during regular visits at the Division of Endocrinology (University Hospital Würzburg). In case of contraindications for a diagnostic procedure (e.g. metallic implants not allowing for a cardiac MRI), patients will not undergo the particular procedure but will still be able to participate in the study. The same applies for patients who are not able or not willing to undergo certain procedures (e.g. inability to perform a chair rising test due to severe myopathy).

In order to elucidate the effects of endogenous CS, results from affected patients and controls without CS will be compared (e.g. evaluating their respective cardiac morphology and function, as described by transthoracic echocardiography and cardiac MRI). For this, subjects from two German population-based studies will be matched for possible contributors (mainly age, gender, and hypertension). A matching ratio of 1:2 (patients with CS to controls without CS) will be aimed for.

Prospective Characteristics and Course of Heart Failure Stages A-B and Determinants of Progression (STAAB) cohort study is a population-based study of inhabitants aged 30 to 79 years from the general population of Würzburg (Germany) [20]. STAAB includes a representative cohort of 5000 men and women without previous history of heart failure at baseline. As the echocardiographic workup in STAAB and CV-CORT-EX will be identical (i.e., the same investigators will apply the same diagnostic tools according to standardised operating procedures), even subtle effects of glucocorticoid excess on echocardiographic parameters will hopefully be detected [20, 24].

The Study of Health in Pomerania-Trend (SHIP-Trend) is a population-based, longitudinal study conducted in North-East Germany [21]. It is based on a representative sample including adult men and women aged between 20 and 79 years from the study region. Baseline examinations were conducted in 4420 men and women between 2008 and 2012. This study will particularly be used to elucidate differences in the cardiac MRI of patients with endogenous CS and controls without the disease.

In addition, data from both population-based studies will also be used to compare the results from other diagnostics applied in the CV-CORT-EX study (e.g. from 24-h ECG, 24-h blood pressure monitoring, and questionnaire assessment).

The prospective CV-CORT-EX study will be conducted at a single German tertiary referral centre (University Hospital Würzburg) and is designed as an interdisciplinary collaborative project including the Divisions of Endocrinology and Cardiology, and the Comprehensive Heart Failure Centre. CV-CORT-EX combines a cross-sectional and a longitudinal phase. Screening and recruitment of eligible patients registered with an endogenous CS at the Division of Endocrinology will be performed between October 2014 and October 2023. Each patient will be actively invited to participate and will be informed by the study physician that participation is voluntary and that termination is possible at any time. The patient will also be informed about the examinations that should be performed during the study and their potential risks. All patients will be enrolled into the cross-sectional arm and undergo comprehensive phenotyping after written informed consent. Further, patients with overt CS will also qualify for the longitudinal arm. After an intervention resulting in remission of CS (usually surgical removal of the causative tumour), patients will be followed for 12 months (with re-evaluations after 6 and 12 months, i.e. with overt CS at baseline and with CS in remission during follow-up).

Participant retention and completion of study will be promoted through various aspects: a) performance of the most relevant study investigations on a single day; b) continuous support of study participants by the same study staff member(s), including organisation of ambulatory sampling procedures and organisation of transports and hospital visits; c) early communication between study participants and study staff member(s) to schedule re-visits (applying a study calendar with all relevant dates, timelines, and deadlines for each individual). Data from patients who decide to withdraw their study consent will be excluded.

CV-CORT-EX aims to comprehensively describe CV health as well as CV related comorbidities in patients with endogenous CS. In particular, our intention is to assess the association of presence and magnitude of glucocorticoid excess to the extent of left ventricular (LV) impairment. Our present data will be compared with those obtained from a control group (matched for relevant contributors like age, sex, and hypertension). Table 2 summarises primary and secondary objectives of the study.

At each study visit, a detailed standardised medical history will be recorded, particularly focusing on CV risk factors (i.e., arterial hypertension, diabetes mellitus, dyslipidaemia, smoking), other endocrine diagnoses (e.g. hypothyroidism), and the current medication. Arterial hypertension, diabetes mellitus, and dyslipidaemia will be assumed in case of specific pharmacotherapy or pathological results during the visit. Smoking status (i.e., current, former, or non-smoking) will also be recorded. In case of current or former smoking, the number of pack-years will be calculated (20 cigarettes = one pack; one pack per day for one year = one pack year).

Patients will undergo a comprehensive physical examination by an experienced endocrinologist, including assessment of possible CS stigmata (e.g. facial plethora, purple striae, or hirsutism).

Patients’ height and weight will be measured with a Seca 200 scale with an integrated measuring rod (Seca, Hamburg, Germany). Body mass index (BMI) will be calculated, dividing body weight by the square of height in metres (kg/m²).

After a five-minute rest in sitting position, resting blood pressure and heart rate will be measured in triplicate with a BoSo Medicus Prestige blood pressure cuff (BoSo Medicus, Jungingen, Germany) and a 3 M Littmann Classic III stethoscope (3 M, Neuss, Germany). Subsequently, the respective means will be calculated.

A conventional 12-lead ECG will be recorded in recumbent position, using the GE KISS device (GE Healthcare, Munich, Germany).

The circumference of three body sites will be determined with a Seca 206 stretch-resistant tape (Seca, Hamburg, Germany). Patients will have to remain in standing position (with slightly raised arms) and breathe normally during the measurement procedure. Three measurements will be performed: 1) dominant upper arm (between the acromion and olecranon); 2) waist circumference (at the midpoint between the lower margin of the last palpable ribs and the top of the iliac crest); 3) hip (at the level of the widest portion of the buttocks). Subsequently, the waist-to-hip ratio (WHR) will be calculated [25].

Bio-impedance analysis (BIA) will be performed to quantify the proportion of muscle, fat, and water. For this, the patient has to remain in horizontal position for 10 min before starting the test. Two pairs of electrodes will be fixed on the dorsal side of the hand and foot of the dominant side and will then be connected to the impedance analyser BIA 2000-S (Data Input, Wedemark, Germany). Subsequently, resistance, reactance, and phase angle will be measured via computer software, thereby determining body composition (using weight, height, age and sex as additional parameters for the distinct calculations).

With respect to the longitudinal sub-study, facial photographs (frontal and profile view) will be taken from each patient to examine the development of typical CS stigmata over time.

The possibility of myopathy will be indirectly evaluated by measurement of hand grip strength. Patients will grasp a hydraulic Jamar handgrip dynamometer (Patterson Medical, Warrenville, IL, USA) with the arm right-angled and at maximum force. The arithmetic mean of three readings will be calculated for each hand. Limbs with known muscle dysfunction (e.g. due to a former stroke) will be excluded from the analysis.

In addition, each patient will undergo a chair rising test as described elsewhere [26]. In short, patients are asked to rise from a sitting position at a chair of 45 cm height until full knee and hip extension. The arms must be kept crossed over the chests while performing the chair rising test. Five repetitions at maximum speed should be performed starting in sitting and ending in standing position. The read-out is the time needed to execute the task, with longer durations corresponding to more severe muscle weakness and a higher risk of falls [26].

After an overnight fast of at least 8 h, participants will undergo blood sampling between 8:00 and 9:00 a.m. These samples will be used for a comprehensive biochemical evaluation (including hormonal, metabolic, cardiac, and various routine parameters). An overview of the standardised biochemical profile is provided in Table 3. All measurements will be performed at the University Hospital Würzburg.

Presence and remission of CS will be confirmed via evaluation of serum cortisol during the 1-mg-DST, diurnal salivary cortisol profiles (with saliva sampling at five time points throughout a day: 08.00 a.m., 12.00 a.m., 4.00 p.m., 8.00 p.m., and 11.00 p.m.), and 24-h urinary free cortisol (taking into account published criteria, e.g. [22]). Additional biosamples (i.e. urine, blood, saliva) for medical research purposes will also be collected and stored at a local biobank (Interdisciplinary Bank of Biomaterials and Data Würzburg, ibdw) [27]. For this, samples will be transferred to the ibdw within 30 min after their collection before being pseudonymised, centrifuged, aliquoted, and stored at − 80 °C (all steps will be performed according to standardised operating procedures).

To evaluate quality of life and psychosocial status, a total of six questionnaires will be handed out to the participants in printed form. Both the CushingQoL and the Tuebingen CD-25 are disease-specific questionnaires for patients with endogenous CS [28, 29]. While the CushingQoL was established for patients with endogenous CS (irrespective of the underlying aetiology), the Tuebingen CD-25 was specifically developed for patients with Cushing’s disease. Generic health status, generic QoL, anxiety, and depressive and panic disorders will be evaluated by the questionnaires EuroQoL-5D-3L (EQ-5D-3L), Short Form 36 (SF-36), Generalized Anxiety Disorder 7 (GAD-7), and brief Patient Health Questionnaire (brief PHQ-D) [30‐33].

Detailed transthoracic echocardiography will be performed and analysed by well trained personnel, using an ultrasound machine (Vivid 9 and Vivid E95, GE, Horton, Norway) with a 3.5 MHz sector scanner according to the standardised protocol of the Comprehensive Heart Failure Centre Würzburg. Subsequently, each investigation will be reviewed blinded to the previous results. Measurements will include standard variables of myocardial morphology and function as well as more advanced readings like speckle-tracking derived strain imaging and the assessment of myocardial work.

Cardiac MRI scans will always be acquired on clinical 1.5 T and 3.0 T scanners (Achieva (1.5 T) and Achieva DS (3.0 T), Philips Healthcare, Best, The Netherlands). Gadobutrol (Dosage 0.15 mmol/kg, Bayer, Leverkusen, Germany) will be used as contrast agent. According to recommendations published by the Society for Cardiovascular Magnetic Resonance (SCMR), the local protocol contains CINE imaging in short and long axes, flow- measurements in the aorta ascendens and main pulmonary artery, and detection of global and focal fibrosis with late enhancement imaging and parametric mapping. Standard clinical parameters will be analysed according to the recommendations of the SCMR and all data will be stored as Digital Imaging and Communications in Medicine (DICOM) format for further post-processing [34]. The interpretation of the cardiac MRI scans will be performed by a cardiac MRI certified cardiologist and separately reviewed by a blinded experienced cardiologist with special training in cardiac MRI. Discrepant results will be decided in consensus or through involvement of a third investigator.

All study participants will undergo 24-h analyses of heart rate and blood pressure. Heart rate will be recorded using the Philipps Digi Trak XT (Philipps, Hamburg, Germany). Scans will be evaluated by experienced cardiologists, and mean heart rate during day and night time as well as heart rate variability will be derived (i.e. a 24-h ECG). Blood pressure will be recorded using a Custo screen 300 (custo med, Ottobrunn, Germany) blood pressure cuff applied to the left upper arm. Blood pressure measurements will be taken every 15 min (between 6.00 a.m. and 10.00 p.m.) or every 30 min (between 10.00 p.m. and 6.00 a.m.). Mean blood pressure during day and night time and dipping status will be evaluated.

The Endo-PAT2000 device (Itamar medical, Israel) offers non-invasive evaluation of endothelial function and will be used according to the manufacturer’s instructions. A blood pressure cuff will be attached to the non-dominant arm and probes to each index finger. After a preparatory phase of 6 minutes, the arterial blood flow into the arm will be interrupted via the blood pressure cuff. After 5 minutes of hypoxemia the blood pressure cuff will be removed to re-establish blood circulation. Vasodilatation will be assessed via measurement of increasing pulse wave deflection (peripheral arterial tone, PAT) via an integrated plethysmograph. Endothelial function will be assessed via the reactive hyperaemia index defined as ratio of the post-to-pre occlusion PAT amplitude of the occluded side, divided by the post-to-pre occlusion ratio of the control side. Arterial stiffness will be evaluated via the augmentation index quantified via pulse waveform analysis of the PAT signal and normalised to a heart rate of 75 bpm.

Source data are the electronically generated original results of technical examinations, including biochemical analyses. The responsible study team (including physicians and nurses) will enter all collected data into case report forms (CRFs). Missing investigations or data in the CRFs will be flagged, along with a statement on the specific reason. Corrections will be made in accordance with Good Clinical Practice (GCP) guidelines, i.e. the version to be corrected will be crossed out so that it is still legible. The corrections (or other entries) will be marked with the date, hand sign and, if necessary, the reason for the changes conducted by the investigator. Incorrect entries will not be covered with correction fluid, erased, or otherwise rendered illegible. Finally, all data will be transferred into an excel file by the responsible study team. The investigator will maintain a patient identification list which will enable the unique assignment of patient numbers to patient name, date of birth, and sex.

Due to the rarity of the disease and the paucity of literature, reliable data on cardiac morphology and function in patients with endogenous CS are lacking. Accordingly, this is an explorative study only (i.e. without formal calculation of case numbers), and the collected data will be used for a post-hoc power analysis. The estimated number of participants is n = 140 patients. The target cohorts will be n = 40 (for patients with newly diagnosed or recurrent overt CS), n = 80 (for patients with CS in remission), and n = 20 (for patients with MACE).

Results will be interpreted on the basis of a complete-case analysis. Missing data or investigations that cannot be interpreted will be excluded. Distribution of data will be evaluated by the Shapiro-Wilk test and quantile-quantile plots, as appropriate. Data will be reported by mean (SD), median (quartiles), and count (percent), as appropriate. Χ²-test, Mann-Whitney U-test or Kruskal-Wallis test will serve to compare groups. Changes from baseline to follow-up will be assessed using Wilcoxon’s signed-rank test. Univariable associations will be analysed with the Spearman’s rho coefficient. ANCOVA models and multivariable linear regression models will be applied to examine the impact of cofactors or potential confounders on crude or change variables.